Aryeh Sand

Aryeh Sand is a Partner in the Healthcare group focused on nuclear medicine, radiopharmaceutical, contrast media and diagnostic imaging, and specialty and generic pharmaceuticals. He joined the firm in 2022 as Managing Director.

Aryeh has 15+ years of healthcare investment banking experience and specializes in advising clients in the nuclear medicine, radiopharmaceutical, contrast media and diagnostic imaging, and specialty and generic pharmaceuticals industries. He has advised boards of directors and special committees as well as companies on a broad range of transactions, including mergers, acquisitions, divestitures, leveraged buyouts, restructurings and capital raising solutions.

Prior to joining Solomon Partners, Aryeh was a Managing Director and Head of Healthcare Investment Banking at TAP Advisors where he spent six years building the firm’s healthcare effort. Prior to TAP, Aryeh was a founding member and senior banker in Mizuho’s Healthcare Investment Banking group. Over the past decade, Aryeh has advised or has served as a lead financing banker on numerous key healthcare transactions with a total transaction value of over $100 billion. Aryeh has worked with leading companies, including Lantheus, Curium (Mallinckrodt Nuclear Medicine), SOFIE, BWXT Medical, Allergan, Amgen, Gilead, Azurity Pharmaceuticals, Upsher-Smith, and Alora Pharmaceuticals.